BioNTech's BNT113 AHEAD-MERIT trial misses first dual primary endpoint

BioNTech reported that its AHEAD-MERIT Phase 2/3 clinical trial did not meet the first dual primary endpoint of progression-free survival for mRNA cancer immunotherapy candidate BNT113 plus pembrolizumab compared with pembrolizumab alone.

Detected & updated continuously · Source: Nebula